ICCPP ODM+ Won Two Muse Design Gold Awards, Keeping Leading the Creative Design Trend
15.9.2023 15:00:00 EEST | Business Wire | Press release
Recently, the winners of MUSE Design Awards 2023, known as the Oscar Awards of the design, were announced, and ICCPP ODM+'s Cyclo eco-friendly e-cigarette and SPEEX X1, one of SPEEX dual-coils and screen display series display products, stood out and won Gold Awards of Muse Design from nearly 40,000 works worldwide, thanks to their advanced globalization vision, innovative user-centered design, and sustainable concepts of caring for both human beings and nature.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904756304/en/
ICCPP ODM+ Won MUSE DESIGN GOLD AWARDS (Photo: Business Wire)
MUSE Design Awards was founded in 2015 by International Awards Associates (IAA), a long-established U.S.-based international design awards association, and is one of the most influential international awards in the field of global creative design. The awards have always been known for their rigorous judging system and high quality standards, aiming to cultivate, promote and recognize excellence in the global design field, and promote the development of the global design industry to a higher level.
ICCPP ODM+ won the two design gold awards in one go in its first competition, which was not only a confirmation of its global leadership in future-oriented innovative product design, concepts and inspirations, but also a recognition of the strength of ICCPP Group's user-centered approach to deepening innovation and empowering the development of the e-atomization industry, and even set a new benchmark for global brands in e-cigarette product design.
It is understood that one of the Gold Award winners, SPEEX X1 is an independent innovative flagship product of the SPEEX heating technology series with high-capacity, dual coil and screen display from ICCPP ODM+, listed in August. It is a unique combination of dual-coil design with dual output working models and SPEEX rocket-like heating technology, and plus the small, rounded, extremely compact and aesthetic design, superimposed on the 0.73-inch oversized e-liquid and power remain screen display, SPEEX X1 achieves a perfect balance among the flavor, vapor, aesthetics and user thinking.
Cyclo, the other winner of Muse Design Gold Awards, is a new 2ml product launched by ICCPP ODM+ at VAPER EXPO UK2023 in May. Considering global trend of low carbon and environmentally friendly concept, coupled with the deep concerns of global users about increasingly serious environmental problems caused by the prevalence of disposable e-cigarettes, as well as the enforce reality of Europe's new Battery Law and some environmental protection acts, ICCPP ODM+ innovatively developed Cyclo, the world's first double environmentally-friendly concept disposable e-cigarettes solution. Through its innovative application of PLA degradable materials, coupled with lead-free and solder-free inner structures, and modularized and fully automated design, as well as the aesthetics of simple, rounded and hand-held shape, and the creative integration of the concepts of user detachable and biodegradable, Cyclo is ahead of the industry to achieve the balance of portability, artistry and recyclability for the users in advance.
While these two award-winning products are just a small microcosm of ICCPP ODM+'s human-centered, and user-first design philosophy. At ICCPP, we believe that design is not just about aesthetics, but should also keep upgrading user experience, meeting user needs and creating a more meaningful connection between people, society and nature. In the future, ICCPP ODM+ will continue to be committed to continuous innovation, to lead the design trend, to create more and more exciting and premium e-cigarette product solutions, and to bring a healthier and happier e-atomized life to vaping enthusiasts around the world.
For more information, please refer to: https://www.iccpp.com/
WARNING: This product contains nicotine which is a highly addictive substance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904756304/en/
Contact information
Media:
Carol, carol@iccpp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom